PreprintBrief ReportVersion 1Preserved in Portico This version is not peer-reviewed
Plasma Cell-free RNA PD-L1 Compared to Tissue PD-L1 Protein Expression and Outcomes with First-line Immunotherapy in Metastatic Non-small Cell Lung Cancer
Version 1
: Received: 16 June 2023 / Approved: 19 June 2023 / Online: 19 June 2023 (12:57:52 CEST)
How to cite:
Walker, P.R.; Jayananda, S.; Pasli, M.; Muzaffar, M. Plasma Cell-free RNA PD-L1 Compared to Tissue PD-L1 Protein Expression and Outcomes with First-line Immunotherapy in Metastatic Non-small Cell Lung Cancer. Preprints2023, 2023061358. https://doi.org/10.20944/preprints202306.1358.v1
Walker, P.R.; Jayananda, S.; Pasli, M.; Muzaffar, M. Plasma Cell-free RNA PD-L1 Compared to Tissue PD-L1 Protein Expression and Outcomes with First-line Immunotherapy in Metastatic Non-small Cell Lung Cancer. Preprints 2023, 2023061358. https://doi.org/10.20944/preprints202306.1358.v1
Walker, P.R.; Jayananda, S.; Pasli, M.; Muzaffar, M. Plasma Cell-free RNA PD-L1 Compared to Tissue PD-L1 Protein Expression and Outcomes with First-line Immunotherapy in Metastatic Non-small Cell Lung Cancer. Preprints2023, 2023061358. https://doi.org/10.20944/preprints202306.1358.v1
APA Style
Walker, P.R., Jayananda, S., Pasli, M., & Muzaffar, M. (2023). Plasma Cell-free RNA PD-L1 Compared to Tissue PD-L1 Protein Expression and Outcomes with First-line Immunotherapy in Metastatic Non-small Cell Lung Cancer. Preprints. https://doi.org/10.20944/preprints202306.1358.v1
Chicago/Turabian Style
Walker, P.R., Melisa Pasli and Mahvish Muzaffar. 2023 "Plasma Cell-free RNA PD-L1 Compared to Tissue PD-L1 Protein Expression and Outcomes with First-line Immunotherapy in Metastatic Non-small Cell Lung Cancer" Preprints. https://doi.org/10.20944/preprints202306.1358.v1
Abstract
Tissue programmed death ligand-1 (PD-L1) protein is the recognized predictive immune biomarker of immune checkpoint inhibitor (ICI) treatment benefit in metastatic non-small cell lung cancer (NSCLC). However, tissue PD-L1 protein testing can be limited by tumor heterogeneity and fraught with tissue acquisition difficulties. A plasma PD-L1 assay potentially overcomes these tissue limitations. Patients with metastatic NSCLC treated with first-line ICI-based treatment and available results of plasma cfRNA PD-L1 by real-time polymerase chain reaction (RT-PCR) and tissue PD-L1 protein PD-L1 with the Dako 22C3 monoclonal antibody were retrospectively assessed for median and landmark 3-year overall survival (OS). OS was identical whether positive plasma cfRNA PD-L1 expression or positive tissue PD-L1 protein expression (median OS 15 months; 3-year landmark OS 30%; hazard ratio (HR) 0.97; 95% CI, 0.44-2.10). Positive plasma cfRNA PD-L1 patients also demonstrated a numerically longer median and higher 3-year OS compared to patients lacking PD-L1 expression (median 15 months versus 8 months; 3-year landmark OS 30% versus 15%; HR 0.56; 95% CI, 0.27-1.17). Plasma cfRNA PD-L1 expression by RT-PCR was similarly predictive of ICI-based treatment benefit as tissue PD-L1 protein expression.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
